{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:08:44Z","timestamp":1784862524105,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amsterdam UMC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In primary prostate cancer (PCa) patients, accurate staging and histologic grading are crucial to guide treatment decisions. <jats:sup>18<\/jats:sup>F-DCFPyL (PSMA)-PET\/CT has been successfully introduced for (re)staging PCa, showing high accuracy to localise PCa in lymph nodes and\/or osseous structures. The diagnostic performance of <jats:sup>18<\/jats:sup>F-DCFPyL-PET\/CT in localizing primary PCa within the prostate gland was assessed, allowing for PSMA-guided targeted-prostate biopsy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty patients with intermediate-\/high-risk primary PCa were prospectively enrolled between May 2018 and May 2019 and underwent <jats:sup>18<\/jats:sup>F-DCFPyL-PET\/CT prior to robot-assisted radical prostatectomy (RARP). Two experienced and blinded nuclear medicine physicians assessed tumour localisation within the prostate gland on PET\/CT, using a 12-segment mapping model of the prostate. The same model was used by a uro-pathologist for the RARP specimens. Based on PET\/CT imaging, a potential biopsy recommendation was given per patient, based on the size and PET-intensity of the suspected PCa localisations. The biopsy recommendation was correlated to final histopathology in the RARP specimen. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for clinically significant PCa (csPCa, Gleason score\u2009\u2265\u20093\u2009+\u20094\u2009=\u20097) were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The segments recommended for potential targeted biopsy harboured csPCA in 28\/30 patients (93%), and covered the highest Gleason score PCa segment in 26\/30 patient (87%). Overall, 122 of 420 segments (29.0%) contained csPCa at final histopathological examination. Sensitivity, specificity, PPV and NPV for csPCa per segment using <jats:sup>18<\/jats:sup>F-DCFPyL-PET\/CT were 61.4%, 88.3%, 68.1% and 84.8%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>When comparing the PCa-localisation on <jats:sup>18<\/jats:sup>F-DCFPyL-PET\/CT with the RARP specimens, an accurate per-patient detection (93%) and localisation of csPCa was found. Thus, <jats:sup>18<\/jats:sup>F-DCFPyL-PET\/CT potentially allows for accurate PSMA-targeted biopsy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-020-03490-8","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T07:02:41Z","timestamp":1603177361000},"page":"2439-2446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Detection of prostate cancer with 18F-DCFPyL PET\/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2524-2538","authenticated-orcid":false,"given":"Y. J. L.","family":"Bodar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. H. E.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"van der Voorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J. C.","family":"Zwezerijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Nieuwenhuijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. H.","family":"Hendrikse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. S.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J. A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"3490_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M et al (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356\u2013387. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.005","journal-title":"Eur J Cancer"},{"key":"3490_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"3490_CR3","unstructured":"Mottet N, Bellmunt J, Briers E, Bolla M, Bourke L, Cornford P et al (2020) EAU \u2013 ESTRO \u2013 ESUR \u2013 SIOG Guidelines on Prostate Cancer. Arnhem, The Netherlands. EAU Guidelines Office"},{"key":"3490_CR4","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/j.juro.2013.02.072","volume":"189","author":"MA Bjurlin","year":"2013","unstructured":"Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D et al (2013) Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol 189:2039\u20132046. https:\/\/doi.org\/10.1016\/j.juro.2013.02.072","journal-title":"J Urol"},{"key":"3490_CR5","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.juro.2008.01.049","volume":"179","author":"BR Lane","year":"2008","unstructured":"Lane BR, Zippe CD, Abouassaly R, Schoenfield L, Magi-Galluzzi C, Jones JS (2008) Saturation technique does not decrease cancer detection during follow-up after initial prostate biopsy. J Urol. 179:1746\u20131750. https:\/\/doi.org\/10.1016\/j.juro.2008.01.049","journal-title":"J Urol."},{"key":"3490_CR6","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767\u20131777. https:\/\/doi.org\/10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"key":"3490_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/s1470-2045(18)30569-2","volume":"20","author":"O Rouviere","year":"2019","unstructured":"Rouviere O, Puech P, Renard-Penna R, Claudon M, Roy C, Mege-Lechevallier F et al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 20:100\u2013109. https:\/\/doi.org\/10.1016\/s1470-2045(18)30569-2","journal-title":"Lancet Oncol"},{"key":"3490_CR8","doi-asserted-by":"publisher","first-page":"012663","DOI":"10.1002\/14651858.CD012663.pub2","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ et al (2019) Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Datab Syst Rev 4:012663. https:\/\/doi.org\/10.1002\/14651858.CD012663.pub2","journal-title":"Cochrane Datab Syst Rev"},{"key":"3490_CR9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","volume":"38","author":"S Perner","year":"2007","unstructured":"Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P et al (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696\u2013701. https:\/\/doi.org\/10.1016\/j.humpath.2006.11.012","journal-title":"Hum Pathol"},{"key":"3490_CR10","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81\u201385","journal-title":"Clin Cancer Res"},{"key":"3490_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s41824-018-0044-0","volume":"2","author":"M Wondergem","year":"2018","unstructured":"Wondergem M, van der Zant FM, Roeleveld TA, Srbljin S, Kartachova MS, van Dongen A et al (2018) 18F-DCFPyL PET\/CT in primary staging of prostate cancer. Eur J Hybrid Imaging 2:26. https:\/\/doi.org\/10.1186\/s41824-018-0044-0","journal-title":"Eur J Hybrid Imaging"},{"key":"3490_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14506","author":"PJ van Leeuwen","year":"2018","unstructured":"van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S et al (2018) 68Ga PSMA PET\/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high-risk prostate cancer. BJU Int. https:\/\/doi.org\/10.1111\/bju.14506","journal-title":"BJU Int"},{"key":"3490_CR13","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.180124","author":"H Wu","year":"2019","unstructured":"Wu H, Xu T, Wang X, Yu YB, Fan ZY, Li DX et al (2019) Diagnostic performance of (6)(8)gallium labelled prostate-specific membrane antigen positron emission tomography\/computed tomography and magnetic resonance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy: a systematic review and meta-analysis. World J Men\u2019s Health. https:\/\/doi.org\/10.5534\/wjmh.180124","journal-title":"World J Men's Health"},{"key":"3490_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30314-7","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study. Lancet. https:\/\/doi.org\/10.1016\/s0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"3490_CR15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D'Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969\u2013974. https:\/\/doi.org\/10.1001\/jama.280.11.969","journal-title":"JAMA"},{"key":"3490_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2967\/jnumed.115.154336","volume":"56","author":"SP Rowe","year":"2015","unstructured":"Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N et al (2015) (1)(8)F-DCFBC PET\/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med 56:1003\u20131010. https:\/\/doi.org\/10.2967\/jnumed.115.154336","journal-title":"J Nucl Med"},{"key":"3490_CR17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.222505","author":"BHE Jansen","year":"2019","unstructured":"Jansen BHE, Kramer GM, Cysouw MCF, Yaqub MM, de Keizer B, Lavalaye J et al (2019) Healthy tissue uptake of (68)Ga-prostate specific membrane antigen (PSMA), (18)F-DCFPyL, (18)F-Fluoromethylcholine (FCH) and (18)F-Dihydrotestosterone (FDHT). J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.118.222505","journal-title":"J Nucl Med"},{"key":"3490_CR18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227520","author":"BHE Jansen","year":"2019","unstructured":"Jansen BHE, Yaqub M, Voortman J, Cysouw MCF, Windhorst AD, Schuit RC et al (2019) Simplified methods for quantification of (18)F-DCFPyL uptake in patients with prostate cancer. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.119.227520","journal-title":"J Nucl Med"},{"key":"3490_CR19","doi-asserted-by":"crossref","unstructured":"Popescu LM, Matej S, Lewitt RM (2004) Iterative image reconstruction using geometrically ordered subsets with list-mode data. In: Nuclear science symposium conference record, 2004, pp 3536\u20133540","DOI":"10.1109\/NSSMIC.2004.1466649"},{"issue":"Suppl 1","key":"3490_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/bju.14794","volume":"124","author":"MJ Scheltema","year":"2019","unstructured":"Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B et al (2019) Diagnostic accuracy of (68) Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of (68) Ga-PSMA PET to mpMRI. BJU Int 124(Suppl 1):42\u201349. https:\/\/doi.org\/10.1111\/bju.14794","journal-title":"BJU Int"},{"key":"3490_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2967\/jnumed.117.195255","volume":"59","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA (2018) Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. J Nucl Med. 59:479\u2013485. https:\/\/doi.org\/10.2967\/jnumed.117.195255","journal-title":"J Nucl Med."},{"key":"3490_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.002","author":"P Cornford","year":"2016","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al (2016) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.002","journal-title":"Eur Urol."},{"key":"3490_CR23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.189233","author":"C Kesch","year":"2017","unstructured":"Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E et al (2017) Intra-individual comparison of 18F-PSMA-1007-PET\/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer\u2014a retrospective, proof of concept study. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.116.189233","journal-title":"J Nucl Med"},{"key":"3490_CR24","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00259-016-3346-0","volume":"43","author":"FL Giesel","year":"2016","unstructured":"Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M et al (2016) Intra-individual comparison of (68)Ga-PSMA-11-PET\/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging 43:1400\u20131406. https:\/\/doi.org\/10.1007\/s00259-016-3346-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3490_CR25","doi-asserted-by":"publisher","first-page":"574e1\u2013e24","DOI":"10.1016\/j.urolonc.2019.05.015","volume":"37","author":"S Dekalo","year":"2019","unstructured":"Dekalo S, Kuten J, Mabjeesh NJ, Beri A, Even-Sapir E, Yossepowitch O (2019) 68Ga-PSMA PET\/CT: does it predict adverse pathology findings at radical prostatectomy? Urol Oncol. 37:574e1\u2013e24. https:\/\/doi.org\/10.1016\/j.urolonc.2019.05.015","journal-title":"Urol Oncol."},{"key":"3490_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s13139-017-0476-7","volume":"51","author":"CJ von Klot","year":"2017","unstructured":"von Klot CJ, Merseburger AS, Boker A, Schmuck S, Ross TL, Bengel FM et al (2017) (68)Ga-PSMA PET\/CT Imaging predicting intraprostatic tumor extent, extracapsular extension and seminal vesicle invasion prior to radical prostatectomy in patients with prostate cancer. Nucl Med Mol Imaging 51:314\u2013322. https:\/\/doi.org\/10.1007\/s13139-017-0476-7","journal-title":"Nucl Med Mol Imaging"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-020-03490-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T12:03:23Z","timestamp":1634731403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-020-03490-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3490"],"URL":"https:\/\/doi.org\/10.1007\/s00345-020-03490-8","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Prof. Dr. Boellaard reports the receiving of a grant from Philips Healthcare, outside the submitted work. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional research board of the Amsterdam UMC (location VUmc), and each participant provided informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each participant provided consent for data publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}